What are the recommended dosing guidelines and contraindications for Robaxin (methocarbamol)?

Robaxin (Methocarbamol): Dosing Guidelines and Contraindications

Methocarbamol should be held on the day of surgery and is absolutely contraindicated in patients with known or suspected renal pathology. 1, 2

Contraindications

Absolute contraindications include:

• Known or suspected renal pathology - The polyethylene glycol 300 vehicle in injectable formulations can increase pre-existing acidosis and urea retention in patients with renal impairment 2
• Hypersensitivity to methocarbamol or any injection components 2
• Myasthenia gravis - Methocarbamol interferes with pyridostigmine bromide effects and should not be used in these patients 1

Use with extreme caution in:

• Hepatic disease - Methocarbamol elimination is significantly impaired in patients with liver disease 1
• Kidney disease - Elimination is significantly impaired 1
• Elderly patients with cardiac conditions - Use caution in those with tachycardia, cardiac decompensation, coronary insufficiency, and cardiac arrhythmias 1

Dosing Guidelines

Oral Administration

For acute musculoskeletal conditions:

• Adults: 1,500 mg four times daily (6,000 mg/day total) 3
• Treatment duration: Continue for up to 8 days, but discontinue as soon as pain-free state is achieved 4
• Efficacy: Approximately 60% of patients respond to methocarbamol versus 30% with placebo 3

Injectable Administration (IV/IM)

Maximum dosing limits:

• Total adult dosage should not exceed 30 mL (3 vials = 3 grams) per day for more than 3 consecutive days (except in tetanus treatment) 2
• If condition persists after 3 days, repeat course only after a 48-hour drug-free interval 2

Intravenous administration:

• May be given undiluted directly into vein at maximum rate of 3 mL per minute 2
• Can be added to IV drip of normal saline or 5% dextrose; one vial should not be diluted to more than 250 mL 2
• Do not refrigerate after mixing with IV infusion fluids 2
• Patient should be recumbent during and for 10-15 minutes following injection 2
• Exercise care to avoid vascular extravasation, which may cause thrombophlebitis 2

Intramuscular administration:

• Maximum 5 mL (one-half vial) per gluteal region 2
• May repeat at 8-hour intervals if necessary 2
• Not recommended for subcutaneous administration 2

Moderate symptoms:

• Single 1-gram dose (one 10 mL vial) may be adequate 2
• Usually does not require repetition; oral form sustains relief 2

Severe cases or postoperative conditions:

• Additional 1-gram doses may be repeated every 8 hours up to maximum 3 g/day for no more than 3 consecutive days 2

Special Population: Tetanus

Adults:

• Initial: Inject 1-2 vials directly into tubing of indwelling needle 2
• Additional 10-20 mL may be added to infusion bottle (total up to 30 mL as initial dose) 2
• Repeat every 6 hours until nasogastric tube can be inserted 2
• Oral maintenance: Up to 24 grams daily may be required (crushed tablets suspended in water/saline via NG tube) 2

Pediatric patients:

• Minimum initial dose: 15 mg/kg or 500 mg/m² 2
• May repeat every 6 hours if required 2
• Total dose should not exceed 1.8 g/m² for 3 consecutive days 2

Perioperative Management

Hold methocarbamol on the day of surgical procedure - This is the consensus recommendation from the Society for Perioperative Assessment and Quality Improvement (SPAQI) 1

Rationale for holding:

• Centrally acting mechanism with unclear precise action 1
• Adverse effects include drowsiness, dizziness, bradycardia, and hypotension 1
• Potential interactions with sedatives and anesthetic agents 1

Important Clinical Considerations

Drug interactions:

• Contraindicated with alcohol - Fatal interactions reported due to combined CNS depression from interactive sedative-hypnotic properties; blood methocarbamol concentration of 257 μg/mL combined with blood ethanol of 135 mg/dL resulted in death 5
• Therapeutic methocarbamol concentrations: 24-41 μg/mL 5

Abuse potential:

• Methocarbamol has relatively low likelihood of abuse compared to benzodiazepines and barbiturates 6
• Does not maintain self-injection behavior in animal models 6

Adverse effects:

• Drowsiness, dizziness 1
• Cardiovascular effects: bradycardia, hypotension 1
• Generally well-tolerated with minimal severe adverse effects (7 symptoms in 5 patients in one study) 4

Clinical efficacy in acute low back pain:

• 44% of methocarbamol patients achieved complete pain relief and discontinued early versus 18% with placebo 4
• 67% of patients and 70% of physicians rated treatment as effective (versus 35-36% in placebo group) 4
• Significant improvements in fingertip-to-floor distance and Schober's test measurements 4